(MedPage Today) — The monoclonal antibody dupilumab (Dupixent) led to significant improvements in esophageal distensibility among patients with eosinophilic esophagitis, the randomized REMODEL trial showed.
At 24 weeks, patients taking dupilumab…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
